Matches in Ubergraph for { <https://frink.apps.renci.org/.well-known/genid/B8e245c20d674f1633c6e792138cf4c7e> ?p ?o ?g. }
Showing items 1 to 5 of
5
with 100 items per page.
- B8e245c20d674f1633c6e792138cf4c7e NCIT_P378 "NCI" @default.
- B8e245c20d674f1633c6e792138cf4c7e type Axiom @default.
- B8e245c20d674f1633c6e792138cf4c7e annotatedProperty IAO_0000115 @default.
- B8e245c20d674f1633c6e792138cf4c7e annotatedSource NCIT_C156730 @default.
- B8e245c20d674f1633c6e792138cf4c7e annotatedTarget "An orally available small molecule antagonist of the C-X-C motif chemokine receptor 1 (CXCR1; interleukin-8 receptor alpha; IL8RA) and 2 (CXCR2; interleukin-8 receptor beta; IL8RB), with potential immunomodulating and antineoplastic activities. Upon administration, navarixin binds to and inhibits the activation of CXCR 1 and 2. This inhibits CXCR1/2-mediated signaling, reduces both recruitment and migration of immunosuppressive myeloid-derived suppressor cells (MDSCs) and neutrophils in the tumor microenvironment (TME), inhibits inflammatory processes and abrogates the immunosuppressive nature of the TME. This allows effector cells, such as natural killer (NK) cells and cytotoxic T-lymphocytes (CTLs), to kill and eliminate cancer cells. This inhibits tumor cell migration, metastasis, angiogenesis and tumor cell proliferation. CXCR 1 and 2, G protein-coupled receptor proteins located on myeloid cells and certain tumor cells, play key roles in the immunosuppressive nature of the TME, tumor metastasis, therapy-resistance, myeloid cell suppression, and inflammation." @default.